NICE does not recommend Opdivo (nivolumab) as a cost effective treatment for head and neck cancer.- BMS
The National Institute for Health and Care Excellence (NICE) in draft guidance considered that clinical data shows Opdivo (nivolumab) from BMS provides a significant improvement in overall survival rates as a second-line therapy - after platinum chemotherapy - for squamous cell carcinoma of the head and neck (SCCHN), at least in the short term. However, that benefit came at too high a cost for the NHS and the drug was not cost effective in this setting.
Comment: Opdivo has CHMP recommendation for treatment of head and neck cancer and waits on final EU approval.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.